Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tebapivat in Anemia Due to Lower-Risk Myelodysplastic Syndromes
NCT05490446Phase 2Active, not recruiting
- Sponsor
- Agios Pharmaceuticals
- Start
- Nov 2022
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of tebapivat in myelodysplastic syndrome (MDS), sponsored by Agios Pharmaceuticals. Started Nov 2022; status: active, not recruiting.
02
Drugs
tebapivat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05490446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490446.